Shares of Zoetis Inc (NYSE:ZTS) have been given an average recommendation of “Buy” by the nineteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $84.73.
A number of research firms have recently weighed in on ZTS. Cantor Fitzgerald restated a “buy” rating and set a $98.00 price target on shares of Zoetis in a report on Wednesday, May 16th. BMO Capital Markets restated a “hold” rating and set a $80.00 price target on shares of Zoetis in a report on Wednesday, May 16th. Craig Hallum restated a “buy” rating and set a $94.00 price target (up previously from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Jefferies Financial Group set a $97.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Monday, February 26th.
Zoetis opened at $87.02 on Tuesday, MarketBeat reports. Zoetis has a 1 year low of $59.50 and a 1 year high of $89.25. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. The firm has a market capitalization of $42.22 billion, a P/E ratio of 36.26, a PEG ratio of 1.93 and a beta of 0.98.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. Zoetis’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.53 EPS. research analysts forecast that Zoetis will post 3.06 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be paid a $0.126 dividend. The ex-dividend date is Thursday, July 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.58%. Zoetis’s payout ratio is presently 20.83%.
In other Zoetis news, insider Kristin C. Peck sold 4,877 shares of the firm’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total value of $407,034.42. Following the sale, the insider now directly owns 42,652 shares in the company, valued at approximately $3,559,735.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Navellier & Associates Inc acquired a new stake in Zoetis in the 4th quarter worth $606,000. Lombard Odier Asset Management Switzerland SA grew its position in Zoetis by 13.8% in the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 279,676 shares of the company’s stock worth $20,148,000 after purchasing an additional 34,000 shares during the last quarter. Amalgamated Bank grew its position in Zoetis by 9.5% in the 4th quarter. Amalgamated Bank now owns 64,901 shares of the company’s stock worth $4,675,000 after purchasing an additional 5,633 shares during the last quarter. Westwood Holdings Group Inc. grew its position in Zoetis by 13.3% in the 4th quarter. Westwood Holdings Group Inc. now owns 65,133 shares of the company’s stock worth $4,692,000 after purchasing an additional 7,632 shares during the last quarter. Finally, We Are One Seven LLC acquired a new stake in Zoetis in the 4th quarter worth $120,000. Institutional investors own 90.09% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.